--- title: "BGM Group closes US$12,000,000 private placement of 200,000,000 shares" url: "https://aibio.space/news/bgm-group-closes-us-12-000-000-private-placement-200-000-000-shares/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-09" section: "Financings" tickers: "NASDAQ:BGM" source: "https://www.sec.gov/Archives/edgar/data/1779578/000110465926071604/tm2617275d1_6k.htm" summary: "BGM Group sold 200,000,000 Class A ordinary shares at US$0.06 each, with warrants for up to another 200,000,000 shares, for gross proceeds of US$12,000,000" --- By the aibio.space news desk. Sources - [BGM Group Ltd. 6-K (2026-06-09)](https://www.sec.gov/Archives/edgar/data/1779578/000110465926071604/tm2617275d1_6k.htm) - [BGM Group Ltd. 20-F (2025-01-27): business](https://www.sec.gov/Archives/edgar/data/1779578/000141057825000056/bgm-20240930x20f.htm) - [BGM Group Ltd. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1779578/000110465926085247/) [BGM](https://aibio.space/companies/bgm/) 2026-06-09 # BGM Group closes US$12,000,000 private placement of 200,000,000 shares and warrants Tickers [BGM](https://aibio.space/companies/bgm/) BGM Group sold 200,000,000 Class A ordinary shares at US$0.06 each, with warrants for up to another 200,000,000 shares, for gross proceeds of US$12,000,000. The private placement closed on June 8, 2026. ## Key facts - **Company**: BGM Group Ltd. (NASDAQ: BGM) - **News type**: Financings - **Primary source**: [BGM Group Ltd. 6-K (2026-06-09)](https://www.sec.gov/Archives/edgar/data/1779578/000110465926071604/tm2617275d1_6k.htm) *A conference room set for a meeting. CC0, via rawpixel. The picture shows the field, not the companies named.* BGM Group Ltd. said in a Form 6-K dated June 9, 2026 that it closed a private placement on June 8, 2026. The company said it had earlier signed a securities purchase agreement with certain investors, which it disclosed in a Form 6-K furnished on May 18, 2026. The June report says the placement was for 200,000,000 Class A ordinary shares, at a subscription price of US$0.06 per share, and warrants to buy up to 200,000,000 more Class A ordinary shares. ## Terms of the placement At closing, BGM issued the 200,000,000 shares and the warrants. The shares carry a par value of US$0.00833335 each. Gross proceeds were US$12,000,000. The report is signed by Huandi Zhao, who is listed as a director and co-chief executive officer. The June report does not give the exercise price of the warrants, their term, or whether any cash would come in when they are exercised. It does not state the company's share count before or after the placement, so the scale of the issue against existing shares cannot be read from this document. It also does not give the market price of the Class A shares around the closing, or any discount to that price. ## Who is named The report refers only to "certain investors" and does not name them. It does not name a placement agent, a financial adviser or any law firm acting for the company or the investors. For the earlier disclosure of the agreement, the June report points to a May 18, 2026 report. ## Use of proceeds The June report does not state how the company will use the US$12,000,000. The report is short and makes no statement about operations, cash needs or future financing. ## The company and its structure The annual report filed in January 2025, covering the fiscal year ended September 30, 2024, says BGM was formerly known as Qilian International Holding Group Limited and is an exempted company with limited liability incorporated in the Cayman Islands. The June report gives its principal executive office in Chengdu, in the People's Republic of China. That annual report describes a structure built on two subsidiaries that BGM owns through equity ownership, along with a variable interest entity, Gansu QLS, and its subsidiaries, which BGM does not own through equity ownership. It defines Ahan Antibacterial Paste as a disinfection paste made from a mixture of 11 traditional Chinese herbal ingredients, used to treat refractory chronic skin diseases. Jiuquan Ahan Biotechnology Co., Ltd., which the report calls Ahan, is 100% owned by Gansu QLS. The June report checks Form 20-F as the annual report form the company files. ## What investors are getting The placement gives new holders Class A ordinary shares and warrants at a single price. The report does not describe the rights attached to the shares beyond their par value, and it does not say whether the shares carry any restriction on resale. Because the warrants are described only by their count, a holder cannot tell from this report what they are worth or when they can be used. The company's structure, as the earlier annual report described it, places the operating business behind contractual arrangements with a variable interest entity. The June report does not address that structure or how the placement relates to it. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story BGM BGM Group Ltd. NASDAQ ยท China Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/bgm-group-closes-us-12-000-000-private-placement-200-000-000-shares/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BGM Group closes US$12,000,000 private placement of 200,000,000 shares", 2026-06-09, https://aibio.space/news/bgm-group-closes-us-12-000-000-private-placement-200-000-000-shares/